Fairvalue-Calculator Fairvalue-Calculator
EN DE

STENO (STENO) Fair Value & Analysis

Healthcare · DK · Market cap 46.9M DKK

Pricekr 1.03
Fair Valuekr 0.9900
Upside-3.4%
Quality95/100
Evidence: Low Range kr 0.7400 – kr 1.23

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

STENO (STENO) currently trades at kr 1.03, while our model-based Fair Value estimate is kr 0.9900 — implying the stock looks roughly 3.4% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Stenocare A/S cultivates, produces, imports, distributes, and sells prescription-based medical cannabis products to patients in Denmark and internationally. It offers medical cannabis oil products, including THC, THC/CBD, and CBD, as well as CBD100 oil products. The company was incorporated in 2017 and is based in Randers, Denmark.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +3193% Jiangsu Hengrui Pharmaceuticals Co (600276) -37% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -1% Hansoh Pharmaceutical Group (3692) -37% Divi's Laboratories Limited (DIVISLAB) -70%

Frequently asked questions

Is STENO (STENO) undervalued?
As of Jun 24, 2026, our model estimates a fair value of kr 0.9900 versus a price of kr 1.03 — about −3% (overvalued). Model-based estimate, not financial advice.
What is the fair value of STENO?
Our 21-model fair value for STENO is kr 0.9900 (as of Jun 24, 2026), built from audited fundamentals. The current price is kr 1.03.
What is the quality score of STENO?
STENO has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.